MedPath

Clinical trial of Modified Shenling Baizhu Powder in the treatment of spleen deficiency and dampness turbidity syndrome of chronic nephritis

Phase 1
Not yet recruiting
Conditions
chronic nephritis
Registration Number
ITMCTR2200006570
Lead Sponsor
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

a) Diagnosed as chronic nephritis;
b) TCM syndrome differentiation belongs to spleen and kidney qi deficiency and dampness turbidity syndrome;
c) Age 18 ~ 65 years old;
d) The 24-hour urinary protein content is 0.5g ~ 3g;
e) eGFR>60 ml/(min·1.73m2)

Exclusion Criteria

a) Except purpura nephritis, lupus nephritis and other secondary glomerular diseases;
b) Pregnant and lactating women;
c) Complicated with serious mental disorders or serious cardiovascular, cerebrovascular and liver diseases.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.